Mitochondrial Cytochrome bc₁ Complex as Validated Drug Target: A Structural Perspective

Area of Science:

• Biochemistry
• Structural Biology
• Drug Discovery

Background:

• Mitochondrial respiratory chain Complex III (cytochrome bc1 complex) is a key target for various therapeutic and agricultural agents.
• Existing knowledge on cytochrome bc1 complex function and inhibition is substantial, yet challenges persist regarding drug resistance and cytotoxicity.

Purpose of the Study:

• To review the structural aspects of cytochrome bc1 complexes and their inhibitors.
• To elucidate mechanisms of drug resistance and cytotoxicity from a structural perspective.
• To explore strategies for developing novel drugs by exploiting structural differences.

Main Methods:

• Analysis of atomic-resolution structures of various cytochrome bc1 complexes.
• Examination of structures with bound inhibitors to understand conformational changes and Q-cycle mechanism implications.
• Correlation of structural details with sequence changes to explain drug resistance.

Main Results:

• Detailed structural features of different cytochrome bc1 complexes are presented.
• Conformational changes and Q-cycle mechanism insights derived from inhibitor-bound structures.
• Structural basis for drug resistance identified through coupled sequence and structural analysis.

Conclusions:

• Structural perspective is vital for addressing challenges in cytochrome bc1 complex-targeted drug development.
• Exploiting evolutionary conserved enzyme structural differences can enhance antifungal drug selectivity and reduce cytotoxicity.
• Atomic-level structural insights provide a unique approach to overcoming drug resistance and improving therapeutic outcomes.